Open AccessEfficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
Author(s) -
Yan Zhao,
Lin Cai,
Xiaoyang Liu,
Heng Zhang,
Jianzhong Zhang
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001510
Subject(s) - secukinumab , medicine , psoriasis , psoriasis area and severity index , adverse effect , plaque psoriasis , dermatology , psoriatic arthritis
There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis. We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis.